| answer text |
<p>The following table sets out for 2011, 2012 and 2013, National Health Service spend
on medicines and percentage of spend, for AstraZeneca, Pfizer and GlaxoSmithKline
in primary care only.</p><p> </p><p>This does not include data on NHS use of medicines
in hospitals, as comparable current data sources do not take account of the discounts
available.</p><p> </p><table><tbody><tr><td colspan="7"><p>Net ingredient cost and
proportion of all primary care spend by manufacturer, in England, for the years 2011,
2012 and 2013, based on prescription items dispensed in the community in England.<sup>1</sup></p></td></tr><tr><td><p>
</p></td><td colspan="2"><p>2011</p></td><td colspan="2"><p>2012</p></td><td colspan="2"><p>2013</p></td></tr><tr><td><p>Manufacturer
name</p></td><td><p>Net Ingredient Cost (£000s)</p></td><td><p>Percentage of all Primary
Care</p></td><td><p>Net Ingredient Cost (£000s)</p></td><td><p>Percentage of all Primary
Care</p></td><td><p>Net Ingredient Cost (£000s)</p></td><td><p>Percentage of all Primary
Care</p></td></tr><tr><td><p>AstraZeneca</p></td><td><p>451,931</p></td><td><p>5.5</p></td><td><p>366,037</p></td><td><p>4.7</p></td><td><p>353,981</p></td><td><p>4.5</p></td></tr><tr><td><p>Pfizer</p></td><td><p>771,631</p></td><td><p>9.5</p></td><td><p>521,610</p></td><td><p>6.7</p></td><td><p>408,643</p></td><td><p>5.2</p></td></tr><tr><td><p>GlaxoSmithKline</p></td><td><p>597,634</p></td><td><p>7.3</p></td><td><p>565,881</p></td><td><p>7.2</p></td><td><p>542,992</p></td><td><p>6.9</p></td></tr><tr><td><p>Total
(all primary care expenditure on medicines in England <sup>2</sup>)</p></td><td><p>8,164,364</p></td><td><p>100.0</p></td><td><p>7,840,390</p></td><td><p>100.0</p></td><td><p>7,888,304</p></td><td><p>100.0</p></td></tr></tbody></table><p><em>
</em></p><p><em>Source:</em> Prescription Cost Analysis provided by the Health and
Social Care Information Centre</p><p><em> </em></p><p><em>Notes:</em></p><p><sup>1.
</sup>This may not include spend on those medicines made by the companies that are
also available generically.</p><p><sup>2. </sup>This total relates to all medicines
contained within British National Formulary (BNF) Chapters 1 to 19. The cost of dressings
and appliances contained within BNF Chapters 20 to 23 has been excluded.</p><p> </p>
|
|
